Breaking Finance News

Deutsche Bank announced Victrex PLC (LON:VCT), bumping up its stock price target to 1,650.00GBX today

Just yesterday Victrex PLC (LON:VCT) traded 0.41% higher at 1,713.00GBX. Victrex PLC’s 50-day moving average is 1,732.08GBX and its 200-day moving average is 1,564.21GBX. The last stock price is up 10.09% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 10,952 shares of VCT traded hands, down from an average trading volume of 289,458

In a report released on 11/30/2016 Deutsche Bank increased the stock price target of Victrex PLC (LON:VCT) from 1,600.00GBX to 1,650.00GBX reporting a possible downside of -0.04%.

Previously on 2/15/2016, Peel Hunt released a statement about Victrex PLC (LON:VCT) held steady the target price at 2,100.00GBX. At the time, this indicated a possible upside of 0%.

Recent Performance Chart

Victrex PLC (LON:VCT)

Victrex PLC has 52 week low of 1,275.58GBX and a 52 week high of 1,961.00GBX with a PE ratio of 18.38 and has a market capitalization of 0 GBX.

In addition to Deutsche Bank reporting its stock price target, a total of 15 brokerages have issued a research note on the company. The average stock price target is 1,716.00GBX with 4 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 9 brokerages rating the stock a hold, 1 brokerage rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Victrex PLC (LON:VCT)

Victrex plc is a United Kingdom-based holding company. The Company is engaged in the manufacture and sale of high performance polymers. The Company's operating segments are Victrex Polymer Solutions and Invibio Biomaterial Solutions. The Victrex Polymer Solutions segment focuses on its automotive, aerospace, electronics and energy markets. The Invibio Biomaterial Solutions segment focuses on providing specialist solutions for medical device manufacturers. It offers its services to over 15,000 aircrafts in approximately 40 countries across the world. The Company intends to focus on polyaryletherketones (PAEK) in automotive, aerospace, electronics and energy, downstream integration opportunities and extending into other markets. It also focuses on spine, trauma, dental and orthopedics, delivering solutions based on polyetheretherketone (PEEK) and other enabling polymers. The Company's subsidiaries include Victrex Manufacturing Limited, Invibio Limited and Victrex Trading Limited.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *